IMC Chicago’s Catalyst Pharmaceutical CPRX Stock Holding History

IMC Chicago’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-563,670	Closed	-$14M	–	6412
2026 Q1	$14M	Buy	+563,670	New	+$13.4M	0.01%	1044

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IMC Chicago's CPRX Position: Q2 2026 in Review

IMC Chicago sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 563,670 shares — an estimated $14M sold.

IMC Chicago first reported a position in CPRX in Q1 2026 and held it in 1 quarter. The position peaked at $14M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

IMC Chicago reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 563,670 Catalyst Pharmaceutical shares in Q2 2026, an estimated $14M.
IMC Chicago first reported a position in Catalyst Pharmaceutical in Q1 2026 and held it in 1 quarter.
IMC Chicago's Catalyst Pharmaceutical position peaked at $14M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.